The Journal of Practical Medicine >

2026 , Vol. 42 >Issue 2: 185 - 193

DOI: https://doi.org/10.3969/j.issn.1006-5725.2026.02.003

Oncology: Diagnosis, Treatment and Prevention

The efficacy of sintilimab combined with concurrent chemoradiotherapy in the treatment of oligometastatic non-small cell lung cancer and its influence on the levels of serum VEGF， NF-κB and PD-L1 in patients

  • Huiping ZHU ,
  • Jian JIANG ,
  • Chunfeng WU ,
  • Chen NI ,
  • Yang SUN ,
  • Yu SONG
Expand
  • Department of Oncology，Zhangjiagang First People's Hospital，Zhangjiagang 215600，Jiangsu，China

Received date: 2025-10-24

  Online published: 2026-01-22

Fold

Abstract

Objective To explore the efficacy of sintilimab in combination with concurrent chemoradiotherapy （CCRT） for the treatment of oligometastatic non-small cell lung cancer （NSCLC） and its impact on the levels of serum vascular endothelial growth factor （VEGF）， nuclear transcription factor κB （NF-κB）， and programmed cell death protein ligand-1 （PD-L1） in patients. Methods From April 2020 to July 2024， a total of 150 patients with oligometastatic NSCLC who received treatment at Zhangjiagang First People's Hospital were randomly assigned to the control group （n = 75， CCRT） and the observation group （n = 75， sintilimab + CCRT） using the random number table method. The short-term therapeutic effects， serum tumor markers， immune function， VEGF， NF-κB， and PD-L1 levels of the two groups were compared before and after treatment. Additionally， the toxic and side effects and prognosis were evaluated. Results The observation group exhibited significantly higher objective response rate and disease control rate （59.72% and 83.33% respectively） compared to the other group （40.00% and 68.57% respectively） （P < 0.05）. After treatment， the serum levels of tumor markers， including VEGF， NF-κB， and PD-L1， in the observation group were all significantly lower （P < 0.05）， whereas the levels of CD4+ and the ratio of CD4+/CD8+ were significantly higher （P < 0.05）. After treatment， the observation group achieved significantly higher scores in the total health status and functional dimension of the Quality of Life scale developed by the European Organization for Research and Treatment of Cancer than the other group （P < 0.05）， while having a significantly lower score in the symptom domain （P < 0.05）. The observation group exhibited a higher incidence of immune-related adverse reactions （15.28% vs. 0.00%） （P < 0.05）. There was no statistically significant difference in other toxic and side effects between the two groups （P > 0.05）. The observation group demonstrated better overall survival and progression-free survival functions （P < 0.05）. Conclusions Compared with CCRT， the combination of sintilimab and CCRT can enhance the short-term efficacy in NSCLC patients with oligometastasis， boost their immune function， down-regulate tumor markers as well as the levels of serum VEGF， NF-κB， and PD-L1. This is beneficial for improving the patients' prognosis and does not significantly increase severe adverse effects.

Key words： non-small cell lung cancer; oligometastatic; sintilimab; concurrent chemoradiotherapy; vascular endothelial growth factor; nuclear transcription factor κb; programmed cell death protein ligand-1

Cite this article

Huiping ZHU , Jian JIANG , Chunfeng WU , Chen NI , Yang SUN , Yu SONG . The efficacy of sintilimab combined with concurrent chemoradiotherapy in the treatment of oligometastatic non-small cell lung cancer and its influence on the levels of serum VEGF， NF-κB and PD-L1 in patients[J]. The Journal of Practical Medicine, 2026 , 42(2) : 185 -193 . DOI: 10.3969/j.issn.1006-5725.2026.02.003

References

[1] ZHANG Y， VACCARELLA S， MORGAN E， et al. Global variations in lung cancer incidence by histological subtype in 2020： A population-based study［J］. Lancet Oncol， 2023， 24（11）： 1206-1218. doi：10.1016/S1470-2045（23）00444-8 .
[2] 张耀文， 温晶媛， 汪晨宇， 等. 放疗在免疫联合化疗一线治疗非小细胞肺癌寡转移患者中的应用价值［J］. 中华放射医学与防护杂志， 2025， 45（2）： 91-100. doi：10.3760/cma.j.cn112271-20240902-00332 .
[3] RICCIUTI B， FUSCO F， COOPER A， et al. Neoadjuvant PD-1 and PD-L1 blockade with chemotherapy for borderline resectable and unresectable stage III non-small cell lung cancer［J］. JAMA Oncol， 2025， 11（7）： 735-741. doi：10.1001/jamaoncol. 2025. 1115 .
[4] JEON H， WANG S， SONG J， et al. Update 2025： Management of non-small-cell lung cancer［J］. Lung， 2025， 203（1）： 53. doi：10.1007/s00408-025-00801-x .
[5] ZHANG X， SHAO M， YAO J， et al. NeoSCORE II： Three vs four cycles of neoadjuvant sintilimab + chemotherapy for squamous non-small-cell lung cancer［J］. Future Oncol， 2024， 20（3）： 121-129. doi：10.2217/fon-2024-0026 .
[6] MOLIFE C， BRNABIC A， STEFANIAK V J， et al. Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer： Network meta-analysis［J］. Immunotherapy， 2023， 15（4）： 293-309. doi：10.2217/ imt-2022-0252 .
[7] KOKKOTOU E， GRAPSA D， PAPADOPOULOU A， et al. Soluble PD-L1 and serum vascular endothelial growth factor-B may independently predict prognosis in patients with advanced non-small cell lung cancer treated with pembrolizumab［J］. Cancers， 2025， 17（3）： 421. doi：10.3390/cancers17030421 .
[8] 中华医学会， 中华医学会肿瘤学分会， 中华医学会杂志社. 中华医学会肺癌临床诊疗指南（2018版）［J］. 中华肿瘤杂志， 2018， 40（12）： 935-964. doi：10.3760/cma.j.issn.0253-3766. 2018.12.012 .
[10] EISENHAUER E A， THERASSE P， BOGAERTS J， et al. New response evaluation criteria in solid tumours： Revised RECIST guideline （version 1.1）［J］. Eur J Cancer， 2009， 45（2）： 228-247. doi：10.1016/j.ejca.2008.10.026 .
[11] BERNARDO D C， LI R J， JIMENO C. Validity and reliability of the European organization for research and treatment of cancer quality of life questionnaire core 30 - Tagalog among adult filipinos with differentiated thyroid cancer［J］. J ASEAN Fed Endocr Soc， 2018， 33（2）： 174-180. doi：10.15605/jafes.033.02.10 .
[12] KLUETZ P G， CHINGOS D T， BASCH E M， et al. Patient-reported outcomes in cancer clinical trials： Measuring symptomatic adverse events with the national cancer institute′s patient-reported outcomes version of the common terminology criteria for adverse events （PRO-CTCAE）［J］. Am Soc Clin Oncol Educ Book， 2016， 35： 67-73. doi：10.1200/EDBK_159514 .
[13] IYENGAR P， ALL S， BERRY M F， et al. Treatment of oligometastatic non-small cell lung cancer： An ASTRO/ESTRO clinical practice guideline［J］. Pract Radiat Oncol， 2023， 13（5）： 393-412. doi：10.1016/j.prro.2023.04.004 .
[14] TSAI C J， YANG J T， SHAVERDIAN N， et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer （Consolidative Use of Radiotherapy to Block ［CURB］ oligoprogression）： An open-label， randomised， controlled， phase 2 study［J］. Lancet， 2024， 403（10422）： 171-182. doi：10.1016/S0140-6736（23）01857-3 .
[15] 段景灏， 姜威， 王文卿， 等. 化学免疫治疗联合放疗治疗NSCLC野生型脑寡转移研究［J］. 中华放射肿瘤学杂志， 2025， 34（6）： 545-552. doi：10.3760/cma.j.cn113030-20250318-00101 .
[16] 王豪， 陆筱祎， 王文杰. 老年局部晚期食管癌同步放化疗序贯信迪利单抗免疫治疗的疗效［J］. 实用医学杂志， 2025， 41（3）： 365-370. doi：10.3969/j.issn.1006-5725.2025.03.009 .
[17] 何梓健， 万宁， 梁蔚婷， 等. 真实世界中帕博利珠单抗治疗晚期非小细胞肺癌的有效性与安全性Meta分析［J］. 暨南大学学报（自然科学与医学版）， 2022， 43（4）： 393-405. doi：10. 11778/j.jdxb.20220083 .
[18] CHEN Y， WANG Y， YANG Z， et al. Local consolidative therapy for synchronous oligometastatic non-small cell lung cancer treated with first-line pembrolizumab： A retrospective observational study［J］. Thorac Cancer，2022， 13（5）： 732-741. doi： 10.1111/1759-7714.14312 .
[19] GRAY J E， VILLEGAS A， DANIEL D， et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC［J］. J Thorac Oncol， 2020， 15（2）： 288-293. doi：10.1016/j.jtho.2019.10.002 .
[20] CANKI E， SCHUURBIERS M M， LINDERS T C， et al. Pre-analytical stability of the CEA， CYFRA 21.1， NSE， CA125 and HE4 tumor markers［J］. Tumour Biol， 2024， 46（s1）： S15-S25. doi：10.3233/TUB-220013 .
[21] 王海英， 吴凯， 田胤纯. 血清基质金属蛋白酶-9、细胞角蛋白19片段及血管内皮细胞生长因子水平与非小细胞肺癌患者顺铂治疗效果的关系［J］. 实用医学杂志， 2024， 40（24）： 3452-3457. doi：10.3969/j.issn.1006-5725.2024.24.004 .
[22] HIRAKAWA T， YAMAGUCHI K， FUNAISHI K， et al. Predictive value of circulatory total VEGF-A and VEGF-A isoforms for the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small-cell lung cancer［J］. Cancers， 2025， 17（4）： 572. doi：10.3390/cancers17040572 .
[23] HUA C， GUO Z， DAI M， et al. Lumbrokinase extracted from earthworms synergizes with bevacizumab and chemotherapeutics in treating non-small cell lung cancer by targeted inactivation of BPTF/VEGF and NF-κB/COX-2 signaling［J］. Biomolecules， 2024， 14（7）： 741. doi：10.3390/biom14070741 .
[24] ANTONANGELI F， NATALINI A， GARASSINO M C， et al. Regulation of PD-L1 expression by NF-κB in cancer［J］. Front Immunol， 2020， 11： 584626. doi：10.3389/fimmu.2020.584626 .
[25] 冯晓洁， 雷霏， 刘宏伟， 等. 血清MMP-2、NF-κB水平对进展期胃癌患者新辅助化疗效果的影响及评估价值［J］. 广西医学， 2023， 45（10）： 1143-1147. doi：10.11675/j.issn.0253-4304. 2023.10.02 .
[26] 张静， 毛英. 血清转化生长因子β1、白细胞介素-6、Toll样受体-4、核转录因子κB联合评估非小细胞肺癌放射性肺炎病情严重程度的价值［J］. 实用临床医药杂志， 2024， 28（14）： 12-17. doi：10.7619/jcmp.20234065 .
[27] 杨敏伟， 曾冬香， 杨全良， 等. 信迪利单抗在晚期非小细胞肺癌化疗患者中的应用及对其血清细胞因子、免疫功能的影响［J］. 中国临床药理学杂志， 2022， 38（24）： 2931-2935. doi：10.13699/j.cnki.1001-6821.2022.24.001 .
Options
Outlines

/

〈 〉